Renal denervation is a catheter-based minimally invasive procedure. It is a therapy carried out by radiofrequency or ultrasound ablation for uncontrolled hypertension. Renal denervation is performed through endovascular catheter-based procedure to treat hypertension, which is beyond medication control. The procedure consists of a catheter that emits radiofrequency energy across multiple electrodes.
Radiofrequency pulse is applied to the renal artery, which causes the wall of artery to ablate, reducing the nerve activity, thereby reducing blood pressure. The progress of catheter-based interventional therapies has yielded impressive results in certifying enhanced blood pressure control in patients with complaints of uncontrolled hypertension, vascular, and cardiovascular diseases.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/798
According to the International Journal of Hypertension in 2013, atrial hypertension affects around 24.8% of the global population, posing morbidity and mortality. Rising prevalence of hypertension with inefficient anti-hypertensive medicines, lasting effect of renal denervation, and fast development of renal denervation devices are expected to drive the growth of renal denervation devices market.
The market is expected to grow drastically with the FDA approval of Symplicity HTN-4 renal denervation device, owing to its targeted radiofrequency energy delivery, thereby minimizing the potential threat to surrounding tissues. The market for renal denervation devices and associated processes is also driven by advantages such as higher safety, reduced treatment time, permanent effect, and rising incidence of uncontrolled & treatment-resistant hypertension.
Regional segmentation of the global renal denervation devices market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The renal denervation devices market in Europe is considered to be the biggest, owing to the increasing number of drug-resistant hypertension cases and technological advances for manufacturing efficient devices. According to the American Heart Association estimates in 2013, around 33% (nearly 70 million people) of the U.S. adult population suffer from high blood pressure. The rising occurrence of uncontrolled hypertension and increasing FDA approvals for drugs are expected to be the major factors driving market growth in North America in the forecast period.
Medtronic Plc., St. Jude Medical, ReCor Medical Inc., Boston Scientific Corporation, and Cardiosonic Ltd.